Alarming Low RSV Vaccine Uptake Among Older Adults Highlights Critical Public Health Gaps

Respiratory Syncytial Virus (RSV) poses a significant and often underestimated threat to older adults, with recent data revealing alarmingly low vaccination rates despite the availability of three FDA-approved vaccines. This suggests crucial gaps in public health awareness, clear eligibility guidelines, and efforts to combat vaccine fatigue.

Significant Disease Burden in the Elderly

While traditionally associated with severe illness in infants and young children, RSV is a major cause of serious lower respiratory tract infections, hospitalization, and mortality in adults aged 60 and over. Each year in the US, an estimated 110,000 to 180,000 adults aged 50 and older are hospitalized due to RSV, with annual deaths ranging from approximately 4,000 to 8,000.

RSV infection in older adults typically begins with cold-like symptoms such as a runny nose and cough, but can rapidly progress to severe complications, including:

Pneumonia and lower respiratory tract illness.
Worsening of underlying chronic conditions like Chronic Obstructive Pulmonary Disease (COPD), asthma, and Congestive Heart Failure (CHF).
Cardiovascular events, with studies showing higher rates of heart failure and atrial fibrillation in RSV patients compared to those with influenza.

Vaccination Recommendations and Eligibility

The Centers for Disease Control and Prevention (CDC) and its Advisory Committee on Immunization Practices (ACIP) recommend a single dose of an RSV vaccine (options include GSK’s Arexvy, Pfizer’s Abrysvo, and Moderna’s mRESVIA) for two key groups:

All adults aged 75 and older. This group is considered high-risk due to natural age-related immune decline.
Adults aged 50 to 74 years who are at increased risk of severe RSV disease. Risk factors include chronic heart or lung disease, chronic kidney or liver disease, severe obesity (BMI ≥40 kg/m$^2$), diabetes, a weakened immune system, and residence in a long-term care facility.

Ideally, vaccination should occur in late summer or early fall, preceding the typical RSV season. Current data suggests a single dose offers protection against hospitalization for at least two seasons, though effectiveness is higher in the immediate season.

Alarming Gaps in Vaccine Uptake

Despite the clear risks and the availability of effective vaccines since 2023, national and international data shows a disappointing uptake:

US Data (2023–2025 Seasons): Only an estimated 16.4% of US adults aged 60 and older received an RSV vaccination. Even among those with high-risk health conditions, the percentage remained low.
Specific Age Groups (US): In the first season (August 2023-February 2024), uptake was lowest in the 60-64 age group (4.7%) and highest in the 75-79 age group (14.0%), still well below target levels.
Disparities: Significant disparities exist based on socioeconomic status, geography, race, and ethnicity, with non-Hispanic Black and Hispanic adults showing lower coverage compared to non-Hispanic White adults.

Major Barriers to Increased Vaccination

Healthcare professionals cite several primary barriers hindering higher vaccination rates:

Low Awareness of Risk: Many older adults and even some providers still primarily associate RSV with pediatrics, underestimating its severity in the elderly population.
Vaccine Fatigue and Hesitancy: The increased number of recommended vaccines since the COVID-19 pandemic has led to a general fatigue and apprehension about adding another shot to the schedule.
Confusion over Eligibility: The initial CDC/ACIP recommendation for adults 60 and older involved “shared clinical decision-making,” causing confusion among providers and patients about who precisely qualified.
Accessibility and Cost: While Medicare Part D generally covers the vaccine, navigating insurance and potential co-pays, particularly for the expanded 50-59 age group, presents a challenge for patients and pharmacists.

The Path Forward

To improve protection for this vulnerable population, healthcare providers, especially pharmacists, are urged to:

Intensify Education: Actively inform patients about the high risk of severe RSV disease and its difference from a common cold.
Proactive Screening: Systematically identify at-risk patients (including those with chronic conditions) in pharmacy and clinical settings.
Champion Vaccination: Address patient concerns and actively recommend the RSV vaccine alongside other preventative measures like influenza and COVID-19 shots, noting that co-administration is acceptable.

The modest uptake highlights the urgent need for a more robust and unified public health campaign to ensure equitable access and overcome the psychological and logistical barriers to vaccination against this serious seasonal respiratory threat.